AstraZeneca has successfully overturned a $107.5 million patent infringement verdict related to its cancer drug Tagrisso, after a Delaware federal judge invalidated two patents held by Pfizer's Wyeth LLC. Judge Matthew F. Kennelly ruled that the patents were not sufficiently described and lacked enablement, meaning they could not guide a person skilled in the art to recreate the inventions. This ruling came just months after a jury found AstraZeneca liable for patent infringement in a case initiated by Pfizer, which claimed that Tagrisso infringed on patents related to a breast cancer drug. Despite the court's decision, AstraZeneca maintains that it did not infringe and that Pfizer suffered no damages. The judge's ruling allows AstraZeneca to continue its sales of Tagrisso, which generated significant revenue last year. The case was titled Wyeth LLC v. AstraZeneca Pharmaceuticals LP in the U.S. District Court for Delaware.